/Biogen%20Inc%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Based in Cambridge, Massachusetts, Biogen Inc. (BIIB) is a prominent global biotechnology company dedicated to pioneering advancements in neuroscience. With a market cap of $32.76 billion, Biogen is renowned for its innovative portfolio that enhances patient care through cutting-edge therapies for neurological and neurodegenerative diseases. The company is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1.
Ahead of the event, analysts expect BIIB to report a profit of $3.98 per share, down 1% from $4.02 per share in the year-ago quarter. In the last four quarters, the company has surpassed Wall Street’s bottom-line estimates in three and missed on another occasion.